These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 12816178)

  • 1. Effect of severe renal impairment on the pharmacokinetics and tolerability of the parenteral endothelin antagonist tezosentan.
    van Giersbergen PL; Dingemanse J
    Int J Clin Pharmacol Ther; 2003 Jun; 41(6):261-6. PubMed ID: 12816178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonist.
    Dingemanse J; Clozel M; van Giersbergen PL
    J Cardiovasc Pharmacol; 2002 Jun; 39(6):795-802. PubMed ID: 12021573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects.
    Dingemanse J; Clozel M; van Giersbergen PL
    Br J Clin Pharmacol; 2002 Apr; 53(4):355-62. PubMed ID: 11966665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporin increases the exposure to tezosentan, an intravenous dual endothelin receptor antagonist.
    van Giersbergen PL; Bodin F; Dingemanse J
    Eur J Clin Pharmacol; 2002 Jul; 58(4):243-5. PubMed ID: 12136369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects.
    Dingemanse J; Gunawardena KA; van Giersbergen PL
    Br J Clin Pharmacol; 2006 Apr; 61(4):405-13. PubMed ID: 16542201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.
    Torre-Amione G; Young JB; Durand J; Bozkurt B; Mann DL; Kobrin I; Pratt CM
    Circulation; 2001 Feb; 103(7):973-80. PubMed ID: 11181472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure.
    Torre-Amione G; Durand JB; Nagueh S; Vooletich MT; Kobrin I; Pratt C
    Chest; 2001 Aug; 120(2):460-6. PubMed ID: 11502644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonist.
    van Giersbergen PL; Dingemanse J
    Eur J Clin Pharmacol; 2007 Feb; 63(2):151-8. PubMed ID: 16636870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.
    Lebrec D; Bosch J; Jalan R; Dudley FJ; Jessic R; Moreau R; Garcia-Pagan JC; Mookerjee RP; Chiossi E; Van Giersbergen PL; Kusic-Pajic A; Dingemanse J
    Eur J Clin Pharmacol; 2012 May; 68(5):533-41. PubMed ID: 22101624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of severe renal impairment on the pharmacokinetics of clazosentan.
    Bruderer S; Sasu B; Tsvitbaum N; Dingemanse J
    J Clin Pharmacol; 2011 Mar; 51(3):413-21. PubMed ID: 20926750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
    Torre-Amione G; Young JB; Colucci WS; Lewis BS; Pratt C; Cotter G; Stangl K; Elkayam U; Teerlink JR; Frey A; Rainisio M; Kobrin I
    J Am Coll Cardiol; 2003 Jul; 42(1):140-7. PubMed ID: 12849674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of liver cirrhosis on the pharmacokinetics, pharmacodynamics, and safety of tezosentan.
    Dingemanse J; Halabi A; van Giersbergen PL
    J Clin Pharmacol; 2009 Apr; 49(4):455-64. PubMed ID: 19318695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of mild liver impairment on the pharmacokinetics of tezosentan, a drug excreted unchanged into bile.
    Dingemanse J; van Giersbergen PL
    Br J Clin Pharmacol; 2004 Mar; 57(3):344-8. PubMed ID: 14998431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.
    Cotter G; Kiowski W; Kaluski E; Kobrin I; Milovanov O; Marmor A; Jafari J; Reisin L; Krakover R; Vered Z; Caspi A
    Eur J Heart Fail; 2001 Aug; 3(4):457-61. PubMed ID: 11511432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure.
    Schalcher C; Cotter G; Reisin L; Bertel O; Kobrin I; Guyene TT; Kiowski W
    Am Heart J; 2001 Aug; 142(2):340-9. PubMed ID: 11479476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of gender on the tolerability, safety and pharmacokinetics of clazosentan following long-term infusion.
    van Giersbergen PL; Dingemanse J
    Clin Drug Investig; 2007; 27(11):797-802. PubMed ID: 17914898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Hasselblad V; Chandler B; Frey A; Kobrin I; Rainisio M; Shah MR; Teerlink J; Gheorghiade M;
    J Am Coll Cardiol; 2003 May; 41(9):1452-7. PubMed ID: 12742280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use.
    Clozel M; Ramuz H; Clozel JP; Breu V; Hess P; Löffler BM; Coassolo P; Roux S
    J Pharmacol Exp Ther; 1999 Aug; 290(2):840-6. PubMed ID: 10411600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
    McMurray JJ; Teerlink JR; Cotter G; Bourge RC; Cleland JG; Jondeau G; Krum H; Metra M; O'Connor CM; Parker JD; Torre-Amione G; van Veldhuisen DJ; Lewsey J; Frey A; Rainisio M; Kobrin I;
    JAMA; 2007 Nov; 298(17):2009-19. PubMed ID: 17986694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets.
    Chin A; Radhakrishnan J; Fornell L; John E
    J Pediatr Surg; 2001 Dec; 36(12):1824-8. PubMed ID: 11733915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.